<DOC>
	<DOCNO>NCT02466581</DOCNO>
	<brief_summary>This international ( Nordic ) trial design compare safety efficacy active conventional therapy ( ACT ) three biologic treatment ( Certolizumab-pegol , Abatacept Tocilizumab ) subject early rheumatoid arthritis ( RA ) . The global aim study assess compare two alternative de-escalation strategy patient achieve low disease activity first-line therapy NORD-STAR study .</brief_summary>
	<brief_title>Dose Reduction Early Rheumatoid Arthritis Patients With Low Disease Activity</brief_title>
	<detailed_description>There currently 10 patient include study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Subject enrol NORDSTAR study accord study inclusion criterion ( meet exclusion criterion study ) . 2 . Subject lowdiseaseactivity accord : 2.8 &lt; CDAI ≤ 10.0 , week 56 NORDSTAR study , i.e . 24 week randomization . 3 . Subject 3 tender 28 joint . 4 . According investigator opinion remain finding due significant active disease ( RA ) . 5 . Female subject either childbearing potential ( postmenopausal , surgically sterile etc . ) , childbearing potential practice one follow method birth control throughout study 150 day study completion : Intrauterine device ( IUD ) Contraceptives ( oral , parenteral , patch ) three month prior study drug administration ) A vasectomized partner 6 . Subject judge good general health determine principal investigator . 7 . Subject must able willing provide write informed consent comply requirement study protocol . 1 . Subject leave NORDSTAR study due moderate high disease activity ( CDAI ≥ 10.0 ) medically important event ( ) . 2 . Patient eligible treatment part 2 ( A B ) NORDSTAR study . 3 . Active infection kind ( exclude fungal infection nail bed ) , major episode infection require hospitalization within 4 week prior randomization . 4 . Subject poorly control medical condition , uncontrolled diabetes , unstable heart disease , congestive heart failure , recent cerebrovascular accident condition , opinion investigator , would put subject risk participation study . 5 . Subject history clinically significant hematologic ( e.g. , severe anemia , leukopenia , thrombocytopenia ) , renal liver disease ( e.g. , fibrosis , cirrhosis , hepatitis ) . 6 . Subject history neurologic symptom suggestive central nervous system ( CNS ) demyelinate disease and/or diagnosis central demyelinate disease . 7 . Subject history cancer lymphoproliferative disease . Allowable exception : 1 . Successfully treat cutaneous squamous cell basal cell carcinoma 2 . Localized carcinoma situ cervix 3 . Curatively treated malignancy ( treatment terminate ) &gt; 5 year prior randomization . 8 . Subject history listeriosis , histoplasmosis , untreated TB , persistent chronic infection , recent active infection require hospitalization treatment intravenous ( i.v . ) antiinfectives within 30 day oral antiinfectives within 14 day prior randomization . 9 . Female subject pregnant breastfeeding consider become pregnant study within 150 day last dose study medication . 10 . Men plan father child time include study . 11 . Subject history clinically significant drug alcohol usage last year . 12 . Subject chronic widespread pain syndrome . 13 . Subject consider investigator , reason , unsuitable candidate study . 14 . Subject unwilling comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>